These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18089865)

  • 1. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
    Grimison P; Galettis P; Manners S; Jelinek M; Metharom E; de Souza PL; Liauw W; Links MJ
    J Clin Oncol; 2007 Dec; 25(36):5704-9. PubMed ID: 18089865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
    Patel SR; Gandhi V; Jenkins J; Papadopolous N; Burgess MA; Plager C; Plunkett W; Benjamin RS
    J Clin Oncol; 2001 Aug; 19(15):3483-9. PubMed ID: 11481354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
    Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
    Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
    Veltkamp SA; Beijnen JH; Schellens JH
    Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
    Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
    J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
    Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
    J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
    Simon N; Romano O; Michel P; Pinçon C; Vasseur M; Lemahieu N; Barthélémy C; Hebbar M; Décaudin B; Odou P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):865-71. PubMed ID: 26193987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
    Pollera CF; Ceribelli A; Crecco M; Oliva C; Calabresi F
    Invest New Drugs; 1997; 15(2):115-21. PubMed ID: 9220290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
    Poplin EA; Corbett T; Flaherty L; Tarasoff P; Redman BG; Valdivieso M; Baker L
    Invest New Drugs; 1992 Aug; 10(3):165-70. PubMed ID: 1428726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
    Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
    J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
    Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
    Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questions about gemcitabine dose rate: answered or unanswered?
    Gandhi V
    J Clin Oncol; 2007 Dec; 25(36):5691-4. PubMed ID: 18089862
    [No Abstract]   [Full Text] [Related]  

  • 20. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.